Top

Pituitary

Published in:

01-06-2015

Gamma knife radiosurgery for Cushing’s disease and Nelson’s syndrome

Authors: Josef Marek, Jana Ježková, Václav Hána, Michal Kršek, Roman Liščák, Vilibald Vladyka, Ladislav Pecen

Published in: Pituitary | Issue 3/2015

Abstract

Purpose

This paper presents our 18 years of experience in treating ACTH secreting adenomas (Cushing’s disease and Nelson’s syndrome) using the Leksell gamma knife (LGK) irradiation.

Methods

Twenty-six patients with Cushing’s disease were followed-up after LGK irradiation for 48–216 months (median 78 months). Seventeen patients had undergone previous surgery, in nine patients LGK irradiation was the primary therapy. Furthermore, 14 patients with Nelson’s syndrome were followed-up for 30–204 months (median 144 months).

Results

LGK treatment resulted in hormonal normalization in 80.7 % of patients with Cushing’s disease. Time to normalization was 6–54 months (median 30 months). The volume of the adenoma decreased in 92.3 % (in 30.7 % disappeared completely). There was no recurrence of the disease. In all 14 patients with Nelson’s syndrome ACTH levels decreased (in two patients fully normalized) their ACTH levels. When checked up 5–10 years after irradiation regrowth of the adenoma was only detected in one patient (9.1 %), in 27.3 % adenoma volume remained unchanged, in 45.4 % adenoma volume decreased and in 18.2 % adenoma completely disappeared. Hypopituitarism did not develop in any patient where the critical dose to the pituitary and distal infundibulum was respected.

Conclusion

LGK radiation represents an effective and well-tolerated option for the treatment of patients with Cushing’s disease after unsuccessful surgery and may be valuable even as a primary treatment in patients who are not suitable for, or refuse, surgery. In the case of Nelson’s syndrome it is possible to impede tumorous growth and control the size of the adenoma in almost all patients.

Biller BMK, Grosssman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay LR, Newel-Price J, Nieman LK, Petersenn S, Sonino N, Stalla K, Swearingen B, Vance ML, Waas JAH, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462CrossRefPubMedCentralPubMed

Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R (2007) Long-term follow up results of postoperative radiation therapy for Cushing’s disease. J Neurooncol 84:79–84CrossRefPubMed

Starke RM, Williams BJ, Vance ML, Sheehan JP (2010) Radiation therapy and stereotactic radiosurgery for the treatment of Cushing’s disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes 17:356–364CrossRefPubMed

Ježková J, Marek J, Hána V, Kršek M, Weiss V, Vladyka V, Liščák R, Vymazal J, Pecen L (2006) Gamma knife radiosurgery for acromegaly—long-term experience. Clin Endocrinol 64:588–595CrossRef

Ježková J, Hána V, Kršek M, Weiss V, Vladyka V, Liščák R, Vymazal J, Pecen L, Marek J (2009) Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol 70:732–741CrossRef

Liščák R, Vladyka V, Marek J, Šimonová G, Vymazal J (2007) Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir 149:999–1006CrossRefPubMed

Brada M, Ajithkumar TV, Minniti G (2004) Radiosurgery for pituitary adenomas. Clin Endocrinol 61:531–543CrossRef

Minniti G, Brada M (2007) Radiotherapy and radiosurgery for Cushing’s disease. Arq Bras Endocrinol Metabol 51:1373–1380CrossRefPubMed

Oldfield EH (2010) Unresolved issues: radiosurgery versus radiation therapy; medical suppression of growth hormone production during radiosurgery; and endoscopic surgery versus microscopic surgery. Neurosurg Focus 29:E16CrossRefPubMed

10.

Novotný J Jr, Vymazal J, Novotný J, Tlachačová D, Schmitt M, Chuda P, Ugrošík D, Liščák R (2005) Does new magnetic resonance imaging technology provide better geometrical accuracy during stereotactic imaging?. J Neurosurg 102(Suppl):8–13CrossRefPubMed

11.

Marek J, Ježková J, Hána V, Kršek M, Bandúrová L, Pecen L, Vladyka V, Liščák R (2011) Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 164:169–178CrossRefPubMed

12.

Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, Plowman PN (2009) Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol 161:819–828CrossRefPubMed

13.

Kobayashi T, Kida Y, Mori Y (2002) Gamma knife radiosurgery in the treatment of Cushing disease: long-term results. J Neurosurg 97(Suppl 5):422–428PubMed

14.

Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML (2007) Gamma knife surgery for Cushing’s disease. J Neurosurg 106:980–987CrossRefPubMed

15.

Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML (2011) Gamma knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 114:303–309CrossRefPubMed

16.

Pollock BE, Brown PD, Nippolt TB, Young WF Jr (2008) Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery 62:1271–1278CrossRefPubMed

17.

Wan H, Chihiro O, Yuan S (2009) MASEP gamma knife radiosurgery for secretory pituitary adenomas: experience in 347 consecutive cases. J Exp Clin Cancer Res 28:36–44CrossRefPubMedCentralPubMed

18.

Castro DG, Cecilio SAJ, Canteras MM (2010) Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety. Radiat Oncol 5:109–115CrossRefPubMedCentralPubMed

19.

Höybye C, Grenbäck E, Rähn T, Degerblad M, Thorén M, Hulting AL (2001) Adrenocorticotropic hormone-producing tumors: 12 to 22-year follow up after treatment with stereotactic radiosurgery. Neurosurgery 49:284–291CrossRefPubMed

20.

Vladyka V, Liščák R, Novotný J Jr, Marek J, Ježková J (2003) Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas. Neurosurgery 52:309–317CrossRefPubMed

21.

Leenstra JL, Tanaka S, Kline RW, Brown PD, Link MJ, Nippoldt TB, Young WF Jr, Pollock BE (2010) Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 67:27–32CrossRefPubMed

22.

Feigl GC, Pistracher K, Berghold A, Mokry M (2010) Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of hypothalamus. J Neurosurg 113(Suppl.):153–159PubMed

23.

Sicignano G, Losa M, del Vecchio A, Cattaneo GM, Picozzi P, Bolognesi A, Mortini P, Calandrino R (2012) Dosimetric factors associated with pituitary function after gamma knife surgery (GKS) of pituitary adenomas. Radiother Oncol 104:119–124CrossRefPubMed

24.

Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96:1992–2003CrossRefPubMed

25.

Pollock BE (2012) Comparing radiation therapy and radiosurgery for pituitary adenoma patients. World Neurosurg 78:58–59CrossRefPubMed

26.

Minniti G, Traish D, Ashley S, Gonsalves A, Brada M (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. J Clin Endocrinol Metab 90:800–804CrossRefPubMed

27.

Rowe J, Grainger A, Walton L, Silcocks P, Radatz M, Kemeny A (2007) Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 60:60–65PubMed

28.

Kajiwara K, Saito K, Yoshikawa K, Ideguchi M, Nomura S, Fujii M, Suzuki M (2010) Sterotactic radiosurgery/radiotherapy for pituitary adenomas: a review of recent literature. Neurol Med Chir 50:749–755CrossRef

29.

Kim W, Clelland C, Yang I, Poratian N (2012) Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas. Surg Neurol Int 3(Suppl. 2):S79–S89PubMedCentralPubMed

30.

Pollock BE, Young WF Jr (2002) Stereotactic radiosurgery for patients with ACTH—producing pituitary adenomas after prior adrenalectomy. Int J Radiation Oncol Biol Phys 54:839–841CrossRef

31.

Vik-Mo EO, Øksnes M, Pedersen P-H, Wentzel-Larsen T, Rodahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M (2009) Gamma knife stereotactic radiosurgery of Nelson’s syndrome. Eur J Endocrinol 160:143–148CrossRefPubMed

32.

Sheehan JP, Zhiyuan X, Salvetti DJ, Schmitt PJ, Lee Vance MJ (2013) Results of gamma knife surgery for Cushing’s disease. J Neurosurg 119:1486–1492CrossRefPubMed

33.

Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF (2002) Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg 97:525–530CrossRefPubMed

34.

Jane JA, Vance ML, Woodburn CJ, Laws ER Jr (2003) Sterotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus 14:e12CrossRefPubMed

35.

Castinetti F, Nagai M, Dufour H, Kuh J-M, Morange I, Jaquet P, Conte-Devolx B, Regis J, Brue T (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol 156:91–98CrossRefPubMed

36.

Tinnel BA, Henderson MA, Witt TC, Fakiris AJ, Worth RM, Des Rosiers PM, Edmondson JW, Timmerman RD, Lo SS (2006) Endocrine response after gamma knife—based sterotactic radiosurgery for secretory pituitary adenoma. Sterotact Funct Neurosurg 86:292–296CrossRef

37.

Losa M, Picozzi P, Redaelli MG, Laurenzi A, Mortini P (2010) Pituitary radiotherapy for Cushing’s disease. Neuroendocrinology 92(Suppl 1):107–110CrossRefPubMed

38.

Wolffenbutell BH, Kitz K, Beuls EM (1998) Beneficial gamma-knife radiosurgery in a patient with Nelson’s syndrome. Clin Neurol Neurosurg 100:60–63CrossRef

39.

Mauermann WJ, Sheehan JP, Chernavvsky DR, Steiner L, Vance ML (2007) Gamma knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J Neurosurg 106:988–993CrossRefPubMed

Title: Gamma knife radiosurgery for Cushing’s disease and Nelson’s syndrome
Authors: Josef Marek
Jana Ježková
Václav Hána
Michal Kršek
Roman Liščák
Vilibald Vladyka
Ladislav Pecen
Publication date: 01-06-2015
Publisher: Springer US
Published in: Pituitary / Issue 3/2015
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-014-0584-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan’s syndrome on standard replacement therapy: a case control study

Evaluation of survivin splice variants in pituitary tumors

Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases

Persistent self-consciousness about facial appearance, measured with the Derriford appearance scale 59, in patients after long-term biochemical remission of acromegaly

Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center

Extracapsular en bloc resection in pituitary adenoma surgery

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials